Background: Clinical trials with a concurrent control group were lacking in the framework of a systematic review on patients with rhabdomyosarcoma treated with autologous hematopoietic stem cell transplantation after preceding high-dose chemotherapy. Further, case series with aggregate survival data were scarce. A pooled analysis of individual data on survival may contribute to the interpretation of scarcely published information. Objectives: To explore whether a pooled analysis of individual data from case reports and case series on survival can be feasible. Methods: Eligible studies were retrieved from MEDLINE, EMBASE and CENTRAL. Pooled individual data were subjected to a Kaplan-Meier survival analysis. The beginning of the follow-up was defined as the time of the transplantation or the precedent high-dose chemotherapy. Results: We found 50 case reports and case series reporting individual data of 185 transplanted patients. Only 42% (78 of 185) of the pooled data were used for the analysis. The data of the remaining 107 patients could not be considered because the required information was incomplete, not stated in the article, or the time of diagnosis was defined as the beginning of the follow-up. Conclusions: Information required for a pooled analysis of individual data on survival of patients with rhabdomyosarcoma treated with autologous hematopoietic stem cell transplantation after preceding high-dose chemotherapy was frequently not stated in case reports and case series and thus hampered the analysis considerably.